Genprex, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GNPX Nasdaq 2836 www.genprex.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Genprex, Inc.

Genprex Provides Clinical Update on Diabetes Gene Therapy Program - Jan 7th, 2026 5:00 am
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies - Jan 6th, 2026 5:00 am
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - Nov 24th, 2025 5:00 am
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials - Nov 19th, 2025 5:00 am
Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - Nov 18th, 2025 5:00 am
Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer - Nov 4th, 2025 5:00 am
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - Oct 28th, 2025 9:19 am
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 28th, 2025 5:00 am
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - Oct 23rd, 2025 6:12 am
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 23rd, 2025 5:00 am
Q3 Virtual Investor Summit: On-Demand Presentations Now Available - Sep 30th, 2025 11:00 am
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free - Sep 16th, 2025 6:00 am
Ryan Confer, President and Chief Executive Officer of Genprex, Inc., to Present at Investor Summit Virtual on September 16, 2025 - Sep 10th, 2025 7:00 am
BC-Most Active Stocks - Sep 8th, 2025 8:30 am
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences - Sep 2nd, 2025 6:30 am
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers - Aug 18th, 2025 7:29 am
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update - Aug 4th, 2025 6:30 am
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions - Jun 24th, 2025 7:25 am
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions - Jun 23rd, 2025 7:00 am
Genprex to Participate at BIO 2025 International Convention - Jun 3rd, 2025 5:00 am